Biomarker-guided treatment for early breast cancer before surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed stage II or III breast cancer (not spread to distant organs).
- Your tumor is ER-positive (ER more than 10%) and HER2-negative (tested by IHC or FISH showing 0–1+).
- You plan to have the breast tumor surgically removed after the pre-surgery (neoadjuvant) treatment, and have measurable or large enough disease on scans.
- You are postmenopausal and can do usual pre-surgery treatments your doctor recommends (an aromatase inhibitor and anthracycline/taxane chemotherapy).
- Your health is good enough for treatment (ECOG 0–1) and your blood counts/organs are within safe ranges.
- You can safely complete breast MRI with IV contrast.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.